CM-156

CM-156 is a nootropic compound developed by the Russian Academy of Sciences. It is a derivative of Phenylpiracetam, but with a higher potency and a broader range of effects.

History

CM-156 was developed by the Russian Academy of Sciences as part of their ongoing research into nootropic compounds. It is a derivative of Phenylpiracetam, a well-known nootropic that has been in use since the 1980s. The aim of the research was to develop a compound with a higher potency and a broader range of effects than Phenylpiracetam.

Pharmacology

CM-156 is a dopamine receptor agonist, meaning it stimulates the dopamine receptors in the brain. This can lead to increased focus, motivation, and mood. It also has antioxidant properties, which can protect the brain from damage caused by free radicals.

Clinical Trials

As of now, there have been limited clinical trials conducted on CM-156. However, preliminary studies suggest that it may have potential as a treatment for conditions such as Alzheimer's disease, Parkinson's disease, and stroke.

Side Effects

The side effects of CM-156 are not well-studied. However, as a derivative of Phenylpiracetam, it may share some of the same side effects, such as insomnia, irritability, and nausea.

See Also

• Nootropics
• Phenylpiracetam
• Dopamine receptor
• Alzheimer's disease
• Parkinson's disease
• Stroke

CM-156 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia